Silvia Taylor

Chief Corporate Affairs & Advocacy Officer @ Novavax.
Opinions = own

[Silvia Taylor @SilT2]

@AnjKhem @CDCDirector Great to see you today Anjalee, and enjoyed seeing both your panels today! Silvia

[Silvia Taylor @SilT2]

Honored to join the Maryland Technology Council's esteemed Board of Directors! I am grateful for the opportunity to contribute to tech innovation, collaborate with industry leaders, and drive growth in this vibrant community.
#techadvancement #Grateful #biotech

[Silvia Taylor @SilT2]

Thanks for having me today for a great conversation!

[Financial Times Live @ftlive]

Pharma marketing – Connecting with patients responsibly

“The third party here is misinformation. There is a lot of misinformation and reliance on channels which you can’t validate for authenticity or truth.”

Silvia Taylor, @Novavax

#FTPharma

[Silvia Taylor @SilT2]

Today, we welcome John Jacobs to the Novavax team. John has already immersed himself in all things Novavax and will be busy meeting with company leaders, employees, and stakeholders in the coming days and weeks. I’m excited to work with you John! Much more to come.

[Novavax @Novavax]

We welcome our new President & CEO John Jacobs to Novavax. John is a seasoned industry leader with more than 25 years of commercial, operations and business experience across therapeutic areas. Learn more: https://t.co/19Z7FyUQZk

[Silvia Taylor @SilT2]

If you’re at @JPMorgan Healthcare Conference, we hope you’ll join Novavax CEO Stan Erck & JPM's Eric Joseph, Ph.D. for our presentation at 5:15pm PST in the Borgia room. Webcast available here: https://t.co/HHpl1zJdyh Replay available on https://t.co/SD0odo7s7u following. #JPM23

[Silvia Taylor @SilT2]

I can’t wait to have John Jacobs and his in-depth industry experience join the team. Much more to come.

Stan – Thank you for your steadfast leadership. You’ve left a lasting legacy on global public health.

[Novavax @Novavax]

Novavax Names John C. Jacobs as New President & CEO
* Current President & CEO Stan Erck to retire
* Novavax is well-positioned to execute on its strategy, with global authorizations for its COVID-19 vaccine and continued clinical pipeline development

https://t.co/qTHQEIoUoj

[Silvia Taylor @SilT2]

I recently visited the UK for the @Jefferies London Healthcare Conference. I always look forward to this annual opportunity to meet investors and discuss Novavax’ plans for the future! I think it was a very productive meeting this year. #Jefferies

[U.S. FDA @US_FDA]

Today, we authorized the Novavax COVID-19 Vaccine, Adjuvanted for use as a first booster dose for individuals 18 & older at least 6 months after completion of primary vaccination with an FDA-approved or authorized COVID-19 vaccine. https://t.co/J5Zdn0b368

[Novavax @Novavax]

NEW: The Novavax #COVID19Vaccine has received emergency use authorization (EUA) from the @US_FDA to provide a two-dose primary series in adolescents aged 12 -17, in addition to the existing 18+ EUA. (🧵1 of 2) Learn more: https://t.co/gvMgJQlLI7

[Novavax @Novavax]

NEW: Novavax submitted our application to the @US_FDA for Emergency Use Authorization for Novavax #COVID19Vaccine as a booster, if authorized, Novavax’ vaccine would be the first protein-based COVID-19 booster for adults. Learn more: https://t.co/fWXZtChKZq
(1/2)

[Novavax @Novavax]

The Novavax COVID-19 Vaccine, Adjuvanted is now on https://t.co/fJtup0s0kd. Visit the site to enter your zip code and find the location nearest you. Locations will continually update, so check back if there is not a location near you.

[Novavax @Novavax]

U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older: https://t.co/tJzlHQbNZo

[Silvia Taylor @SilT2]

We are now in a position to join the mission: helping to protect people living in the United States from COVID-19. I couldn’t be more proud to be part of such a passionate and motivated team. Thank you to each and every one of our #SuperNovas! We did it!

#Covid19

[Silvia Taylor @SilT2]

Today is a very special day for @Novavax. After countless hours of dedication and determination, the Novavax COVID-19 vaccine has been authorized for emergency use as a primary series in individuals 18 across the USA: https://t.co/k6fvz9MGKD

[Novavax @Novavax]

We’ve got big news. Our protein-based #COVID19vaccine is now authorized for 18+ primary series under emergency use in the United States. [🧵1 of 2] Read more: https://t.co/n9Ddg0ozAa

[Novavax @Novavax]

U.S. Government Secures 3.2 Million Doses of Novavax #COVID19Vaccine: https://t.co/lcAOJqsGCw

[Novavax @Novavax]

New: The @EU_Commission has approved the expanded conditional marketing authorization for the Novavax #COVID19Vaccine in the European Union for adolescents aged 12 through 17. Learn more: https://t.co/hUNaWrT3hL

[Novavax @Novavax]

Novavax Statement on Prototype Vaccine’s Broad Immune Responses and Accelerated Focus on Omicron BA.4/5 as Recommended by the FDA: https://t.co/BzYESCEuSt

[Novavax @Novavax]

TODAY: Novavax participated in the FDA VRBPAC meeting which resulted in a 19-2 vote to recommend inclusion of a SARS-CoV-2 Omicron component for #COVID19booster vaccines in the U.S. beginning this fall. https://t.co/W106UXffnz

[Silvia Taylor @SilT2]

Such a great panel today with Lauren Smith (@CDCFound), @DMGrayMD and @lorirosebenson, moderated by @jtrizzino on the “Last Mile” of access to allow vaccines to make a difference. Like Darrell said, ”Change happens at the speed of trust.” I couldn’t agree more! #AspenIdeasHealth